Vitals Knowledge Vault

Melatonin — Safety & Interactions

5 min read

Melatonin — Safety & Interactions

TL;DR

Melatonin has a favorable safety profile relative to most pharmacological sleep aids. The most serious documented interaction is fluvoxamine (17-fold AUC increase via CYP1A2 inhibition — avoid). Caffeine increases melatonin exposure by 120% and is a relevant confounder for sleep quality. Melatonin is not recommended during pregnancy for insomnia indications. Endocrine effects (insulin sensitivity reduction in type 2 diabetics) are clinically relevant for specific populations. Long-term use up to 12 months shows no tolerance, withdrawal, or rebound.

CYP1A2 drug interactions

Melatonin is metabolized primarily by CYP1A2 → 6-hydroxymelatonin → 6-sulfatoxymelatonin (inactive). CYP1A2 inhibitors increase melatonin exposure significantly.

Severe — avoid or drastically reduce dose

DrugEffectMechanismClinical action
Fluvoxamine17× AUC increase (PMID 10668847)Strong CYP1A2 inhibition (50–69%)Avoid melatonin; if unavoidable, use <<0.5 mg and monitor
CiprofloxacinSignificant AUC increaseCYP1A2 inhibitionReduce melatonin dose; monitor for excessive sedation

Moderate — dose adjustment and monitoring

DrugEffectMechanismClinical action
Caffeine120% AUC increase (PMID 14616429)CYP1A2 inhibition; also delays melatonin clearanceReduce melatonin dose if consuming caffeine in the evening; note that caffeine-containing products (coffee, tea, energy drinks) are widely used and often consumed in the evening — this is a common confounder of melatonin efficacy
CimetidineModerate increaseCYP1A2 inhibitionMonitor for excessive sedation
MexiletineModerate increaseCYP1A2 inhibitionMonitor
Quinolone antibiotics (other than ciprofloxacin)Moderate increaseCYP1A2 inhibitionMonitor

Clinical note on caffeine

The caffeine–melatonin interaction is particularly relevant because:

  • Caffeine is widely consumed (coffee, tea, energy drinks, pre-workout)
  • Evening caffeine consumption is common and often undisclosed in coaching contexts
  • A user taking melatonin with evening coffee may experience unexpectedly elevated melatonin levels and next-day drowsiness
  • The interaction is bidirectional: melatonin may increase the subjective intensity of caffeine

Vitals coaching guardrail: Ask about evening caffeine intake before attributing next-day drowsiness to melatonin dose.

Smoking

Smoking induces CYP1A2 → reduces melatonin exposure. Smokers may require higher melatonin doses for equivalent effect. Smoking cessation leads to reduced melatonin clearance — dose reduction may be needed.

Anticoagulants

Case reports of elevated PT/INR with concurrent warfarin + melatonin (PMID 18289163). Proposed mechanism: platelet inhibition.

Vitals coaching action:

  • Users on warfarin or other anticoagulants should have INR monitored closely when adding or discontinuing melatonin
  • Do not prohibit use; monitor INR within 1–2 weeks of starting or stopping melatonin in anticoagulated users
  • Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran): interaction is less characterized; proceed with caution and clinical awareness

Antihypertensives

Melatonin can lower blood pressure via vasodilatory MT2 signaling on vascular smooth muscle.

Vitals coaching action:

  • Additive hypotensive effects are possible; monitor BP in users on antihypertensive medications
  • The effect is generally modest; most users will not experience clinically significant BP reduction
  • More relevant for users on multiple antihypertensives or those with labile BP

Endocrine effects — Diabetes and insulin sensitivity

⚠️ Clinically relevant flag for type 2 diabetics.

A 3-month study (PMID 35619221) found that melatonin supplementation reduced insulin sensitivity in type 2 diabetics. The clinical relevance of this finding for non-diabetics or prediabetics is not well-established, but the direction is worth noting.

Vitals coaching action:

  • Flag for users with T2D or metabolic syndrome: melatonin may modestly reduce insulin sensitivity with chronic use
  • This does not prohibit use but suggests periodic monitoring of fasting glucose and HbA1c for diabetic users on melatonin
  • The risk-benefit calculation for iRBD and DSPD still favors melatonin use in diabetic populations — this is a monitoring flag, not a contraindication

Pregnancy and breastfeeding

  • Pregnancy: Not recommended for insomnia indication during pregnancy due to insufficient safety data (PMID 34730672). However, melatonin is being actively studied as an antioxidant in high-risk pregnancy (preeclampsia, IUGR) at doses up to 75 mg/night with no serious adverse events in Phase I trials (PMID 33432828).
  • Breastfeeding: Melatonin is secreted into breast milk; clinical significance at typical supplement doses is unknown. Use requires individualized risk-benefit assessment.

Vitals coaching action: Pregnant or breastfeeding users with sleep difficulty should consult their OB-GYN before using melatonin. CBT-I remains the first-line recommendation for pregnancy insomnia.

Seizure disorders

Evidence is mixed — some studies show EEG changes with melatonin; others suggest anticonvulsant properties. A case-by-case approach is warranted.

Vitals coaching action:

  • Use with caution in seizure disorder patients
  • Monitor seizure frequency if melatonin is introduced
  • If anticonvulsant properties prove relevant, this would be a benefit in specific populations — the evidence is not yet clear enough to position melatonin as either pro- or anticonvulsant

Contraindications summary

ContraindicationSeverityAction
Hypersensitivity to melatoninAbsoluteDo not use
Concurrent fluvoxamine or strong CYP1A2 inhibitors without dose reductionSevereAvoid; if unavoidable, use <<0.5 mg
Pregnancy (insomnia indication)RelativeDo not recommend; refer to OB-GYN
Seizure disorderRelativeUse with caution; monitor
Type 2 diabetesRelativeMonitor fasting glucose/HbA1c periodically

Long-term safety

  • No tolerance documented up to 12 months of continuous use
  • No withdrawal upon discontinuation
  • No rebound insomnia upon discontinuation
  • Adverse event profile is mild: next-day drowsiness (dose-dependent), headache, dizziness (all low incidence)

This favorable long-term profile distinguishes melatonin from benzodiazepines, Z-drugs, and antihistamines, which all carry documented tolerance and dependence risks.

Next-day drowsiness

Minimal at physiologic doses (0.3–5 mg). Driving/simulation studies show no significant impairment at these doses (PMID 9772309, PMID 18763235).

Recommendation: Avoid driving or operating machinery within 5 hours of melatonin dosing — a conservative guardrail given individual PK variability and the 17-fold AUC variation possible with CYP1A2 inhibitors.

Gonadal axis

No evidence of clinically significant testosterone, LH, or FSH suppression in humans at standard doses (PMID 9404445). Animal data showing HPG axis suppression at high doses are not applicable to human supplementation.

Autoimmune conditions

Theoretical concern: melatonin has immunostimulatory properties in some contexts (increases IL-2, TNF-α, IFN-γ in oncology/immune deficiency populations). Evidence is inconclusive for autoimmune disease populations. Not a absolute contraindication but warrants clinical awareness.

Graph View